The performance of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the expiry in key territories has introduced substantial risk . Investors are now assessing the consequences of rival medications ,